Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $54.50.

A number of research firms have recently weighed in on ORKA. BTIG Research raised their price target on shares of Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. UBS Group started coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Finally, Wedbush boosted their price objective on Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares of the company’s stock, valued at $1,101,162.66. This trade represents a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 21,000 shares of company stock valued at $663,530. 24.69% of the stock is currently owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. increased its stake in shares of Oruka Therapeutics by 777.1% in the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock valued at $4,338,000 after buying an additional 126,803 shares during the period. Virtus Investment Advisers LLC bought a new position in shares of Oruka Therapeutics during the fourth quarter worth about $267,000. RTW Investments LP boosted its position in Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after acquiring an additional 112,499 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Oruka Therapeutics by 16.4% in the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock valued at $44,753,000 after acquiring an additional 208,480 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $1,780,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $35.56 on Wednesday. The stock’s 50-day moving average is $31.94 and its two-hundred day moving average is $25.89. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $36.51. The stock has a market cap of $1.72 billion, a PE ratio of -18.72 and a beta of -0.38.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.